Bartnik Magdalena, Pawlik Weronika, Burzyńska Beata, Wasilewski Konrad, Kamieńska Elżbieta, Urasiński Tomasz
Department of Paediatrics Hemato-Oncology and Paediatric Gastroenterology, Pomeranian Medical University, 70-204 Szczecin, Poland.
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 01-447 Warsaw, Poland.
Genes (Basel). 2024 Dec 7;15(12):1576. doi: 10.3390/genes15121576.
Hexokinase (HK) deficiency is a rare autosomal recessively inherited disease manifested by chronic nonspherocytic hemolytic anemia. Most patients present with a mild to severe course of the disease (fetal hydrocephalus, neonatal hyperbilirubinemia, severe anemia). We reviewed 37 cases of patients with hexokinase deficiency described so far, focusing on the severity of the disease, clinical presentation, treatment applied, and genetic test results.
We present a 10-year-old girl who initially presented with symptoms of weakness, excessive fatigue, and yellowing of the skin and sclerae. Genetic testing detected the (TA)7 variant in both alleles of the UGT1A1 gene and diagnosed Gilbert's disease. In the follow-up, red cell hemolysis was observed. The diagnosis was extended, and tests for red cell enzymopathy were performed and a reduced level of hexokinase-0.65 IU/gHb (normal 0.78-1.57) was found. Next-generation sequencing revealed a new sense-change variant in exon 7 in the hexokinase gene not previously reported in databases.
Up to this date, only around 37 cases of hexokinase deficiency associated with hereditary nonspherocytic hemolytic anemia have been documented around the world. Diagnosing hexokinase deficiency involves clinical evaluation, laboratory testing, and genetic analysis. Management focuses on treating symptoms and preventing complications; there is no cure for the underlying enzyme deficiency. In patients with severe anemia, the treatment is multiple blood transfusions followed by iron chelation therapy.
Understanding and diagnosing hexokinase deficiency is critical for providing appropriate care and improving the quality of life for affected individuals.
己糖激酶(HK)缺乏症是一种罕见的常染色体隐性遗传疾病,表现为慢性非球形红细胞溶血性贫血。大多数患者的病情轻重不一(胎儿脑积水、新生儿高胆红素血症、严重贫血)。我们回顾了迄今为止描述的37例己糖激酶缺乏症患者,重点关注疾病的严重程度、临床表现、应用的治疗方法以及基因检测结果。
我们报告一名10岁女孩,最初表现为虚弱、极度疲劳以及皮肤和巩膜黄染症状。基因检测在UGT1A1基因的两个等位基因中均检测到(TA)7变异,诊断为吉尔伯特病。在随访过程中,观察到红细胞溶血现象。诊断范围扩大,进行了红细胞酶病检测,发现己糖激酶水平降低——0.65 IU/gHb(正常范围为0.78 - 1.57)。新一代测序揭示了己糖激酶基因外显子7中一个新的有义改变变异,该变异此前未在数据库中报道。
截至目前,全球仅记录了约37例与遗传性非球形红细胞溶血性贫血相关的己糖激酶缺乏症病例。诊断己糖激酶缺乏症需要进行临床评估、实验室检测和基因分析。治疗重点是缓解症状和预防并发症;潜在的酶缺乏无法治愈。对于重度贫血患者,治疗方法是多次输血,随后进行铁螯合治疗。
了解和诊断己糖激酶缺乏症对于为受影响个体提供适当护理和提高生活质量至关重要。